Immunic, Inc. Announces Annual Stockholder Meeting on June 11, 2024

TL;DR

<b>Immunic, Inc. is holding its virtual annual stockholder meeting on June 11, 2024, urging shareholders to vote by proxy.</b>

AI Summary

IMMUNIC, INC. (IMUX) filed a Proxy Statement (DEF 14A) with the SEC on April 23, 2024. Immunic, Inc. will hold its annual meeting of stockholders on June 11, 2024. The meeting will be conducted virtually via the Internet at https://web.lumiconnect.com/276702602. No physical meeting will be held. Stockholders are encouraged to vote by proxy over the Internet or by telephone. The company is filing a Definitive Proxy Statement (DEF 14A).

Why It Matters

For investors and stakeholders tracking IMMUNIC, INC., this filing contains several important signals. This filing (DEF 14A) provides essential information for stockholders to understand the agenda and exercise their voting rights for the annual meeting. The virtual format aims to increase accessibility for stockholders to participate in corporate governance, regardless of their location.

Risk Assessment

Risk Level: — IMMUNIC, INC. shows moderate risk based on this filing. The filing is a routine proxy statement for an annual meeting, with no immediate financial or operational disclosures that would indicate high risk.

Analyst Insight

Review the proxy statement to understand the proposals being voted on and consider voting your shares by the deadline.

Key Numbers

• June 11, 2024 — Annual Meeting Date (Date of the annual meeting of stockholders.)
• 9:00 a.m. Eastern time — Annual Meeting Time (Time of the annual meeting of stockholders.)
• DEF 14A — Filing Type (Form type for the proxy statement.)
• 001-36201 — SEC File Number (SEC file number for Immunic, Inc.)

Key Players & Entities

• Immunic, Inc. (company) — Registrant and filer of the proxy statement.
• June 11, 2024 (date) — Date of the annual meeting of stockholders.
• 20240423 (date) — Filing date of the proxy statement.
• 1200 Avenue of the Americas, Suite 200 New York, New York 10036 (address) — Business and mailing address of Immunic, Inc.

FAQ

Industry Context

Immunic, Inc. operates in the pharmaceutical preparations industry, focusing on developing novel therapies.

Regulatory Implications

The filing is made under Section 14(a) of the Securities Exchange Act of 1934, which governs the solicitation of proxies from stockholders.

What Investors Should Do

1. Review the proxy statement for details on proposals and director nominations.
2. Vote your shares by proxy via Internet, telephone, or mail.
3. Attend the virtual annual meeting on June 11, 2024, if possible.

Key Dates

• 2024-06-11: Annual Meeting of Stockholders — Key date for stockholder participation and voting.
• 2024-04-23: Filing Date — Date the Definitive Proxy Statement was filed with the SEC.

Year-Over-Year Comparison

This is a routine DEF 14A filing for an annual meeting and does not appear to be a comparison to a prior filing of the same nature.

Filing Documents

• e663535_def14a-immunic.htm (DEF 14A) — 381KB
• image_004.jpg (GRAPHIC) — 6KB
• image_001.jpg (GRAPHIC) — 50KB
• image_002.jpg (GRAPHIC) — 47KB
• image_003.jpg (GRAPHIC) — 1KB
• image_005.jpg (GRAPHIC) — 1KB
• image_006.jpg (GRAPHIC) — 1KB
• 0001193805-24-000551.txt (&nbsp;) — 529KB

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 28 RELATED PERSON TRANSACTIONS 40

SECURITY OWNERSHIP

SECURITY OWNERSHIP 41 OTHER MATTERS 44 PROPOSALS OF STOCKHOLDERS FOR 2025 ANNUAL MEETING 45 THE BOARD OF DIRECTORS 46 iii IMMUNIC, INC. 1200 Avenue of the Americas, Suite 200 New York, New York 10036 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS Time and Date 9:00 a.m. Eastern time, on June 11, 2024 Place Virtually via the Internet at https://web.lumiconnect.com/276702602. No physical meeting will be held. Items of Business (1) To elect Dr. Daniel Vitt and Dr. Duane Nash as Class I Directors to serve until our 2027 annual meeting of stockholders and until their successors are duly elected and qualified. (2) To ratify the appointment of Baker Tilly US, LLP (&ldquo;Baker Tilly&rdquo;) as our independent registered public accounting firm for the fiscal year ending December 31, 2024. (3) To approve, by non-binding advisory vote, the resolution approving named executive officer compensation. (4) To transact other business that may properly come before the annual meeting. Adjournments and Postponements Any action on the items of business described above may be considered at the annual meeting at the time and on the date specified above or at any time and date to which the annual meeting may be properly adjourned or postponed. Record Date April 22, 2024 Only stockholders of record of our common stock as of the close of business on April 22, 2024 are entitled to notice of and to vote at the annual meeting. Meeting Admission You are invited to attend the annual meeting if you are a stockholder of record or a beneficial owner of shares of our common stock, in each case, as of the close of business on April 22, 2024. If you are a stockholder of record, you must use your 16-digit control number included on your notice, on your proxy card or on the instructions that accompanied your proxy materials, to enter the annual meeting. If you are not a stockholder of record but hold shares as a beneficial owner in &ldquo;street name,&rdquo; you may be re

View Full Filing

View this DEF 14A filing on SEC EDGAR